Nyloxin

Manufacturer: Nutra Pharma Corporation
Effective date: 2025-10-20
Label type: HUMAN OTC DRUG LABEL
Version: 6
Source: full-release
Hydrated at: 2026-06-01 02:37:09

Label at a glance#

ProductNyloxin

Active ingredientNAJA NAJA VENOM

Label structure10 sections

Indications and uses

Temporarily relieves pain associated with sore back, inflamed joints, migraines, painful menses, and general persistent pain

Dosage and administration

Remove clear cap. Press down 4 times to prime the pump. Spray 2 times directly into mouth or under tongue. Use spray initially every 3-4 hours.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Analgesic Topical Gel

Active Ingredients

OTC - ACTIVE INGREDIENT SECTION

Asian Cobra Venom 4x

Purpose

OTC - PURPOSE SECTION

Analgesic*

*Claim based on traditional Homeopathic practices not accepted medical evidence. Not FDA approved.

Uses:

INDICATIONS & USAGE SECTION

Temporarily relieves pain associated with sore back, inflamed joints, migraines, painful menses, and general persistent pain

Warnings:

WARNINGS SECTION

Side effects may include headache, nausea, sore throat, allergic rhinitis, gastrointestinal discomfort.
If symptoms persist or worsen, stop using this product and consult a physician.
When Using This Product: avoid contact with the eyes. If product gets into eyes, flush with water. Seek medical attention.

Directions For Use:

DOSAGE & ADMINISTRATION SECTION

Remove clear cap.
Press down 4 times to prime the pump.
Spray 2 times directly into mouth or under tongue.
Use spray initially every 3-4 hours.

Other Information:

OTHER SAFETY INFORMATION

OTC - DO NOT USE SECTION

Do not use if tamper-proof tab is broken.
This product is NOT intended to treat disease, it can provide a temporary level of comfort, relief and a feeling of wellness.
Th s product has been determined to be safe and effective for moderate to severe (Stage 3) chronic pain, as indicated by the Homeopathic Pharmacopeia of the United States.
Clinical experience suggests Nyloxin may provide relief from other forms of pain.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Pregnant or nursing women and children should consult a physician before use.

Inactive Ingredients:

INACTIVE INGREDIENT SECTION

Flavoring, Purified water, Sodium benzoate, Sodium phosphate, Xylitol

Principal Display Panel - 1 oz Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Chronic Pain Relief

Nyloxin™

ORAL SPRAY ES

• Back Pain
• Neck Pain
• Headaches
• Join Pain
• Migraines
• Neuralgia

BREAKTHROUGH
Stage 3
Pain Relief

EXTRA STRENGTH

1 oz. net wt.

Made in the U.S.A.

Principal Display Panel - 1 oz Carton Label

Principal Display Panel - 1 oz Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Chronic Pain Relief

Nyloxin™
ES

• Back Pain
• Neck Pain
• Headaches
• Join Pain
• Migraines
• Neuralgia

EXTRA STRENGTH
ORAL SPRAY

HOMEOPATHIC

1 oz. net wt.

Principal Display Panel - 1 oz Bottle Label

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
c6f86816-7da6-43ea-8c25-ac9758311cc5	Product name	1	20220118
252e11b6-1a9a-4283-a242-df2c129c496d	Product name	3	20170717

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
47219-210-01	2024-01-30	C162847	48780-1	ba0f9c33-1f34-a910-e053-dadaa90a0b85	Nyloxin Oral Spray ES
47219-210-01	2024-01-30	C162847	48780-1	ba0f9c33-1f34-a910-e053-dadaa90a0b85	DRUG FACTS
47219-210-01	2021-07-14	C162847	48780-1	ba0f9c33-1f34-a910-e053-dadaa90a0b85	Nyloxin Oral Spray ES
47219-210-01	2021-07-14	C162847	48780-1	ba0f9c33-1f34-a910-e053-dadaa90a0b85	DRUG FACTS
47219-210-01	2021-01-29	C162847	48780-1	ba0f9c33-1f34-a910-e053-dadaa90a0b85	Nyloxin Oral Spray ES
47219-210-01	2021-01-29	C162847	48780-1	ba0f9c33-1f34-a910-e053-dadaa90a0b85	DRUG FACTS

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
47219-210-01	Nyloxin	30 mL in 1 BOTTLE, SPRAY	SPRAY, METERED	30		6
47219-210-01	Nyloxin	1 in 1 BOX	SPRAY, METERED	1		6

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
NAJA NAJA VENOM	ACTIVE INGREDIENT	ZZ4AG7L7VM	1
NAJA NAJA VENOM	ACTIVE MOIETY	ZZ4AG7L7VM	1
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	1
SODIUM PHOSPHATE	INACTIVE INGREDIENT	SE337SVY37	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	1
XYLITOL	INACTIVE INGREDIENT	VCQ006KQ1E	1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

Nyloxin
NAJA NAJA VENOM
WATER
SODIUM BENZOATE
SODIUM PHOSPHATE
XYLITOL

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
47219-210	47219-210-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
NAJA NAJA VENOM	ZZ4AG7L7VM	ACTIB
WATER	059QF0KO0R	IACT
SODIUM BENZOATE	OJ245FE5EU	IACT
SODIUM PHOSPHATE	SE337SVY37	IACT
XYLITOL	VCQ006KQ1E	IACT

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
Version	Effective date	Source	Hydrated
5	2022-12-13	full-release	2026-06-01 02:19:07

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 72 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	SUSPENSION / ORAL	40 mg		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, COATED / ORAL	0.2 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	CAPSULE / ORAL	8.5 mg		Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	FILM, SOLUBLE / ORAL		29 mg	Exact identifier — unii+route 20 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET / ORAL	15.04 mg		Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SUSPENSION / ORAL		320 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	POWDER, FOR SOLUTION / ORAL		98 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	GRANULE, EFFERVESCENT / ORAL	60 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SOLUTION / ORAL		660 mg	Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SOLUTION / ORAL		21600 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, FILM COATED / ORAL		1 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	CONCENTRATE / ORAL		20 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	PASTE / ORAL		28 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SUSPENSION/ DROPS / ORAL		23 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, COATED / ORAL	0.2 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SUSPENSION, EXTENDED RELEASE / ORAL		24 mg	Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET, ORALLY DISINTEGRATING / ORAL		360 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	CONCENTRATE / ORAL	NA		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, DELAYED RELEASE / ORAL	0.34 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	PASTE / ORAL		28 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	CONCENTRATE / ORAL	NA		Exact identifier — unii+route 14 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SUSPENSION / ORAL		1500 mg	Exact identifier — unii+route 20 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET, EXTENDED RELEASE / ORAL		2752 mg	Exact identifier — unii+route 20 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	POWDER, FOR SUSPENSION / ORAL	4223 mg		Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	GRANULE / ORAL	NA		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	PASTE / ORAL		180 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	SYRUP / ORAL	1.5 mg/1ml		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SOLUTION / ORAL		660 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET / ORAL	30 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	CONCENTRATE / ORAL		20 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	SUSPENSION / ORAL	40 mg		Exact identifier — unii+route 14 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET, ORALLY DISINTEGRATING / ORAL		360 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	GRANULE, EFFERVESCENT / ORAL	60 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	GRANULE, FOR SUSPENSION / ORAL		120 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	SOLUTION / ORAL	27 mg/5ml		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	INJECTION / ORAL	10.35 mg		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	GRANULE / ORAL	NA		Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SUSPENSION, EXTENDED RELEASE / ORAL		9000 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	CAPSULE / ORAL	36 mg		Exact identifier — unii+route 14 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SUSPENSION, EXTENDED RELEASE / ORAL		9000 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	POWDER, FOR SOLUTION / ORAL		98 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SUSPENSION, EXTENDED RELEASE / ORAL		24 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	TABLET / ORAL	16 mg		Exact identifier — unii+route 14 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SUSPENSION / ORAL		1500 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	SYRUP / ORAL		80 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET, EXTENDED RELEASE / ORAL		2752 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	ELIXIR / ORAL	5.02 mg/5ml		Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET, FILM COATED, EXTENDED RELEASE / ORAL		72 mg	Exact identifier — unii+route 20 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	POWDER, FOR SUSPENSION / ORAL	4223 mg		Exact identifier — unii+route 20 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	TABLET / ORAL	15.04 mg		Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, FILM COATED / ORAL		1 mg	Exact identifier — unii+route 38 equally ranked IID candidates
XYLITOL	XYLITOL	VCQ006KQ1E	SOLUTION / ORAL		21600 mg	Exact identifier — unii+route 20 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	CAPSULE / ORAL	8.5 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	POWDER, FOR SUSPENSION / ORAL		160 mg	Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	TABLET / ORAL	16 mg		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM PHOSPHATE	SODIUM PHOSPHATE	SE337SVY37	INJECTION / ORAL	10.35 mg		Exact identifier — unii+route 14 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET, DELAYED RELEASE / ORAL	0.34 mg		Exact identifier — unii+route 38 equally ranked IID candidates
SODIUM BENZOATE	SODIUM BENZOATE	OJ245FE5EU	TABLET / ORAL	30 mg		Exact identifier — unii+route 38 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Nyloxin	NAJA NAJA VENOM	Nutra Pharma Corporation	153f90b4-2ac7-4217-bd32-0353343f85cc	2025-10-20	Warnings	Exact identifier ndc (package): 47219-210-01 ndc (product): 47219-210 ndc11 (package): 47219021001 spl id: e9a3d402-4d38-445a-bfca-6d8c0d22d613 spl set id: 153f90b4-2ac7-4217-bd32-0353343f85cc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.